Cargando…
Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is one of the main causes of chronic liver disease worldwide. Flavonoids, a group of natural compounds, have garnered a great deal of attention in the management of NAFLD because of their profitable effects on glucose and lipid metabolism, infl...
Autores principales: | Naeini, Fatemeh, Namkhah, Zahra, Tutunchi, Helda, Rezayat, Seyed Mahdi, Mansouri, Siavash, Jazayeri-Tehrani, Seyed Ali, Yaseri, Mehdi, Hosseinzadeh-Attar, Mohammad Javad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590238/ https://www.ncbi.nlm.nih.gov/pubmed/34774104 http://dx.doi.org/10.1186/s13063-021-05784-7 |
Ejemplares similares
-
Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial
por: Jazayeri-Tehrani, Seyed Ali, et al.
Publicado: (2019) -
Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol
por: Jazayeri-Tehrani, Seyed Ali, et al.
Publicado: (2017) -
Effect of Collagen Hydrolysate and Fish Oil on High-Sensitivity C-Reactive Protein and Glucose Homeostasis in Patients with severe Burn; a Randomized Clinical Trial
por: Alipoor, Elham, et al.
Publicado: (2021) -
Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial
por: Daneshi-Maskooni, Milad, et al.
Publicado: (2019) -
Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial
por: Daneshi-Maskooni, Milad, et al.
Publicado: (2018)